Shots:
- Skyhawk Therapeutics has entered into a strategic research collaboration with Merck KGaA to discover novel RNA-targeting small molecules for neurological diseases with limited treatment options
- Skyhawk will receive ~$2B incl. upfront, milestones, & potential tiered royalties, leading discovery & preclinical development, while Merck KGaA gains exclusive global rights & handles further development & commercialization upon option exercise
- Skyhawk will use its SkySTAR platform to identify small molecules against RNA targets designated by Merck KGaA, aiming to advance RNA modulation in hard-to-treat diseases
Ref: Skyhawk Therapeutic| Image: Skyhawk Therapeutic and Merck KGaA | Press Release
Related News:- Eli Lilly Collaborates with Superluminal Medicines to Develop Small Molecule for Cardiometabolic Diseases and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
